Gallery
Photos from events, contest for the best costume, videos from master classes.
 |  |
 |  |
 |  |
 |  |
 |  |
 |  |
With the 1 older placebo-controlled clinical trial that showed no benefit for gabapentin for the treatment of chemotherapy-induced peripheral neuropathy, 66 2 subsequent trials investigating pregabalin as an agent to prevent chemotherapy-induced neuropathy (1 for paclitaxel 43 and 1 for oxaliplatin [ClinicalTrials.gov Identifier: NCT00380874 Introduction Chemotherapy-induced peripheral neuropathy (CIPN) affects patients’ quality of life and treatment effectiveness. Gabapentinoids, like gabapentin and pregabalin, are often used for CIPN treatment, but their efficacy and safety remain uncertain. This study reviews and analyses randomised controlled trial data on this topic. Materials/methods We searched PubMed, Embase and Cochrane When peripheral neuropathy occurs due to chemotherapy treatment, it is referred to as chemotherapy-induced peripheral neuropathy (CIPN). Typically, symptoms are sensory rather than motor and include reduced feeling and heightened sensitivity to Chemotherapy-induced peripheral neuropathy (CIPN) is a common toxicity associated with treatment with platinum-based agents, taxanes, vinca alkaloids, and other specific agents. The long-term consequences of this condition can result in decreased Abstract Objectives: Chemotherapy-induced peripheral neuropathy (CIPN) is a common chemotherapy side effect, but its prevention and treatment remains a challenge. Neurotoxicity may lead to dose limitation or even treatment discontinuation, and therefore potentially affect the efficacy of anticancer treatment and long term outcomes. The practice to administer gabapentin for neuropathy may be Abstract Introduction: Chemotherapy-induced peripheral neuropathy (CIPN) affects patients' quality of life and treatment effectiveness. Gabapentinoids, like gabapentin and pregabalin, are often used for CIPN treatment, but their efficacy and safety remain uncertain. This study reviews and analyses randomised controlled trial data on this topic. Background: The antiepileptic agent, gabapentin, has been demonstrated to relieve symptoms of peripheral neuropathy due to various etiologies. On the basis of these data, a multicenter, double-blind, placebo-controlled, crossover, randomized trial was conducted to evaluate the effect of gabapentin on symptoms of chemotherapy-induced peripheral The clinical pathology of Taxol-induced peripheral neuropathy (TIPN), characterized by loss of sensory sensitivity and pain, is mirrored in a preclinical pharmacological mice model in which Gabapentin, produced anti-thermal hyperalgesia and anti-allodynia ABSTRACT. Objective. This study was conducted to investigate the efficacy and safety of gabapentin monotherapy in the management of chemotherapy-induced ne Drug-induced peripheral neuropathy is a common and painful condition caused by many different and frequently prescribed medications. Most often, DIPN is seen in chemotherapeutic agents, antimicrobials, cardiovascular drugs, psychotropic, and anticonvulsant drugs. Gabapentin, a medication primarily used to treat nerve pain and seizures, has garnered attention for its potential side effects. One of the more concerning discussions revolves around whether gabapentin may contribute to the development of peripheral neuropathy. This condition, characterized by damage to the peripheral nerves, can lead to symptoms like pain, tingling, and weakness in the Gabapentin is an effective option for the treatment of neuropathic pain syndromes because of its efficacy and favorable side-effect profile. A case is presented of a 58 year old man who developed a painful polyneuropathy while being treated with gabapentin. Chemotherapy-induced peripheral neuropathy (CIPN) is a progressive, enduring, and often irre-versible adverse effect of many antineoplastic agents, among which sensory abnormities are common and the most suffering issues. The pathogenesis of CIPN Compared with the control group, gabapentin therapy led to a statistically significant better response in patients of each baseline neurotoxicity group. Conclusions. Gabapentin monotherapy seems to be well tolerated and useful for the management of chemotherapy-induced neuropathic pain. 301 Moved Permanently301 Moved Permanently cloudflare Regarding gabapentin, research has demonstrated its efficacy in alleviating neuropathic pain in surgery-induced or trauma-induced peripheral neuropathy models in diabetic animals. The effects of Gabapentin are well-known in conditions such as post-herpetic neuralgia, painful diabetic neuropathy, spinal cord injury pain, and neuropathic cancer pain. More common cancer-related neuropathic pain syndromes are listed in Table 1. The use of Gabapentin in patients with neuropathic pain can alleviate pain and increase daily Efficacy and safety of oxycodone/naloxone as add-on therapy to gabapentin or pregabalin for the management of chemotherapy-induced peripheral neuropathy in Korea. A randomized, multicenter, blinded, placebo-controlled, crossover, clinical trial was conducted to evaluate the role of gabapentin in patients with symptomatic chemotherapy-induced peripheral neurop INTRODUCTION Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect of cancer therapy that can have a profound impact on quality of life and survivorship [1].
Articles and news, personal stories, interviews with experts.
Photos from events, contest for the best costume, videos from master classes.
| |
| |
| |
| |
| |
| |